Substrate
Topic

stock-ratings

5 stories related to this topic, newest first.

Analysts Initiate Coverage on Three Biotech and Aerospace Stocksthestreet.com
finance5 days ago

Analysts Initiate Coverage on Three Biotech and Aerospace Stocks

Mizuho, Roth Capital, and an unnamed GE Aerospace analyst started coverage on Century Therapeutics, BioAge Labs, and GE Aerospace with positive ratings and price targets.

Benzinga
1 source
Analysts Downgrade Applied Materials and Outlook Therapeutics247wallst.com
finance14 days ago

Analysts Downgrade Applied Materials and Outlook Therapeutics

Morgan Stanley and BTIG analysts lowered ratings on Applied Materials and Outlook Therapeutics. The changes were among several analyst adjustments reported for the trading week.

Benzinga
1 source
J.P. Morgan Downgrades Corning and Fabrinet Despite Raising Price TargetsSubstrate placeholder — needs review
finance46 days ago

J.P. Morgan Downgrades Corning and Fabrinet Despite Raising Price Targets

J.P. Morgan has downgraded Corning and Fabrinet to Neutral ratings while increasing their price targets and revenue forecasts. The downgrades reflect concerns about valuation and near-term visibility despite positive long-term growth expectations.

seekingalpha.com
1 source
Three Real Estate Stocks Identified as Oversold Based on RSI Indicatormedium.com
finance48 days ago

Three Real Estate Stocks Identified as Oversold Based on RSI Indicator

Benzinga reported on three real estate sector stocks with RSI values near or below 30, indicating oversold conditions. The RSI measures momentum by comparing price strength on up days to down days. Such stocks may present buying opportunities for investors seeking undervalued ass…

Benzinga
1 source
BofA Global Research Downgrades NXP Semiconductors Rating to Neutral and Lowers Price TargetSubstrate placeholder — needs review
finance49 days ago

BofA Global Research Downgrades NXP Semiconductors Rating to Neutral and Lowers Price Target

BofA Global Research has changed its rating on NXP Semiconductors from 'buy' to 'neutral'. The firm also reduced its price target for the stock from $245 to $230. This adjustment reflects an update in the analyst's assessment of the company's outlook.

FI
1 source